Biogen (BIIB.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec17

HSBC downgrades Biogen's rating to reduce from hold

22:32

Dec16

LEQEMBI Added to China's Commercial Insurance List of Innovative Drugs

16:17

Stifel Nicolaus analyst maintains buy rating on Biogen

08:22

Dec11

Wells Fargo Analyst Maintains Biogen Hold Rating With A Price Target Of $190

04:32

Dec10

HSBC downgrades Biogen's rating and target price leading to stock price decline

13:43

Dec9

William Blair Analyst Maintains Buy Rating on Biogen

11:07

Schedules & Filings

Schedules

Filings

Oct30

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 2.535 B, Net Income 466.5 M, EPS 3.17

Jul31

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 2.646 B, Net Income 634.8 M, EPS 4.33

May1

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 2.431 B, Net Income 240.5 M, EPS 1.64

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change